Business ❯ Pharmaceutical Industry

Market Competition

Pricing Strategies Drug Pricing Novo Nordisk Eli Lilly Generic Drugs Drug Approval Drug Development Product Launch Weight Loss Drugs Product Development

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

A twice-daily regimen hit key efficacy measures prompting MapLight to seek FDA input on a registrational trial.

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

Novo Nordisk Sues Eli Lilly Over Alleged Misleading GLP‑1 Ads

Novo Nordisk Sues Eli Lilly Over Allegedly Misleading Weight-Loss and Diabetes Ads

DEA Moves to Temporarily Place Concentrated 7‑OH and Three Kratom Derivatives in Schedule I

EU Opens Antitrust Probe Into Sanofi Over Efluelda Flu Vaccine

Novo Nordisk Sues to Annul EMS’s Ozivy Trademark

FDA Panel Weighs Moderna’s Bid for First U.S. mRNA Flu Vaccine

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

Germany Approves Cannabis-Based Drug Exilby for Neuropathic Back Pain

Supreme Court Clears Path for Generic 'Skinny Labels' in Unanimous Hikma Ruling

EMS’s Ozivy Cleared by Anvisa as First Synthetic Semaglutide Pen After Patent Expiry

Brazil Clears First Domestic Semaglutide Pen and Sets Price Ceiling Equal to Ozempic

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

Anvisa Registers Ozivy as Brazil’s First Synthetic Semaglutide Analogue

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

Jury Finds Takeda Liable for Delaying Amitiza Generics, Awards $885 Million

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

Mounjaro Overtakes Keytruda as World’s Best-Selling Drug in Q1 2026